Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the potential effect of withdrawal from the European Medicines Agency on access to new treatments for people with dementia.

The Government has clearly stated the United Kingdom’s desire to work collaboratively with the European Union on the issue of medicines regulation. It is in the interest of patients for us to find a way to continue UK-EU collaboration. We want to make sure patients continue to get rapid access to new and innovative medicines and devices, including treatments for people with dementia, and that the quality, safety and efficacy of those medicines and devices are maintained.